Whitehawk Therapeutics (WHWK) Non Operating Income (2016 - 2026)
Whitehawk Therapeutics (WHWK) reported Non Operating Income of $1.3 million for Q1 2026, down 98.49% year-over-year from $88.2 million in Q1 2025, and down 18.83% on a QoQ basis from $1.6 million in Q4 2025.
Whitehawk Therapeutics (WHWK) has 11 years of Non Operating Income data on file, last reported at $1.3 million in Q1 2026.
- Quarterly Non Operating Income fell 98.49% year-over-year to $1.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.9 million (down 92.4% YoY) and the FY2025 annual result came in at $93.8 million, up 2390.15% from the prior year.
- Non Operating Income slipped to $1.3 million in Q1 2026 per WHWK's latest filing, from $1.6 million in the prior quarter.
- Across five years, Non Operating Income topped out at $88.2 million in Q1 2025 and bottomed at -$43000.0 in Q1 2022.
- The 5-year median for Non Operating Income is $1.4 million (2023), against an average of $6.3 million.
- The widest annual swing landed in 2025, when Non Operating Income jumped 7114.55%; it then tumbled 98.49% in 2026.
- Tracing WHWK's Non Operating Income over 5 years: stood at $1.5 million in 2022, then dropped by 6.77% to $1.4 million in 2023, then sank by 53.22% to $676000.0 in 2024, then surged by 142.01% to $1.6 million in 2025, then fell by 18.83% to $1.3 million in 2026.
- Per Business Quant, the three latest WHWK Non Operating Income figures stand at $1.3 million (Q1 2026), $1.6 million (Q4 2025), and $1.8 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 444,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 201.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -46.98 Mn |
| 10 | Whitehawk Therapeutics | 312.26 Mn | 189.22 Mn | - | 1.33 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.33 Mn |
| Dec 31, 2025 | 1.64 Mn |
| Sep 30, 2025 | 1.80 Mn |
| Jun 30, 2025 | 2.13 Mn |
| Mar 31, 2025 | 88.23 Mn |
| Dec 31, 2024 | 676,000.00 |
| Sep 30, 2024 | 867,000.00 |
| Jun 30, 2024 | 1.00 Mn |
| Mar 31, 2024 | 1.22 Mn |
| Dec 31, 2023 | 1.45 Mn |
| Sep 30, 2023 | 1.55 Mn |
| Jun 30, 2023 | 1.57 Mn |
| Mar 31, 2023 | 1.60 Mn |
| Dec 31, 2022 | 1.55 Mn |
| Sep 30, 2022 | 562,000.00 |
| Jun 30, 2022 | 100,000.00 |
| Mar 31, 2022 | -43,000.00 |
| Dec 31, 2021 | -45,000.00 |
| Sep 30, 2021 | 223,000.00 |
| Jun 30, 2021 | 2.34 Mn |
| Mar 31, 2021 | -1.39 Mn |
| Dec 31, 2020 | -383,000.00 |
| Sep 30, 2020 | -228,000.00 |
| Jun 30, 2020 | 20,119.00 |
| Mar 31, 2020 | 196,270.00 |
| Dec 31, 2019 | 211,089.00 |
| Sep 30, 2019 | 318,708.00 |
| Jun 30, 2019 | 295,303.00 |
| Mar 31, 2019 | 348,468.00 |
| Dec 31, 2018 | 347,588.00 |
| Sep 30, 2018 | 339,441.00 |
| Jun 30, 2018 | 46,464.00 |
| Mar 31, 2018 | 51,116.00 |
| Dec 31, 2017 | 53,829.00 |
| Sep 30, 2017 | 106,671.00 |
| Jun 30, 2017 | 63,555.00 |
| Mar 31, 2017 | -236,118.00 |
| Dec 31, 2016 | -212,556.00 |
| Sep 30, 2016 | -140,286.00 |
| Jun 30, 2016 | -7,829.00 |
| Mar 31, 2016 | 10,745.00 |